Table 1.

Comparison of an animal models under different treatment conditions

	Cell type and number injected	Cell temperature before injection (°C)	Trypsin treatment	Observations
				First appearance of lesions (weeks after injection)	Tumor locations and survival (five mice per group)
1	MPC 10 × 106	4	Long (10 min)	4–5	4–20 in liver (5/5) median survival 68, range 52–84 days
2	MPC 10 × 106	25	Short (1–2 min)	3	>100 in liver (5/5), 1/5 adrenal and 1/5 ovary lesion *liver tumors used to create MTT variant cell line median survival 25, range 22–28 days
3	MTT 10 × 106	25	Short (1–2 min)	2	Tumor embolism (2/5) mice die within days; multiple (>100) liver lesions and pancreas destroyed (3/5),1/5 ovary lesions, 1/5 kidney lesion, median survival 16, range 13–19 days
4	MTT 2 × 106	25	Short (1–2 min)	2	Liver lesions (5/5) on 2 weeks Lung (2/5), ovaries (2/5), and adrenal (3/5) lesions on 3 weeks median survival 28, range 26–30 days
5	MTT 5 × 105	25	Short (1–2 min)	2.5	>40 liver lesions on 3 weeks (5/5), at 4 weeks 3/5 mice with adrenal lesions, 2/5 with lung lesions, 2/5 with ovary lesions, 3/5 mice with bone lesions, median survival 29, range 27–31 days
6	MPC 5 × 105	25	Short (1–2 min)	4.5	20 in liver on 4.5 weeks (5/5), at 5.5 weeks 1/5 to ovary and lungs, median survival 43, range 41–45 days

Starting with the same concentration of MPC injected intravenously and conditions (1) We found storing cells at room temperature prior to injection and reducing the trypsin time yielded more liver tumors which also developed sooner (2) Liver tumors were cultured which yielded MTT cells. The MTT were injected at the same conditions but was lethal in most mice (3) By reducing the number of MTT cells injected, we found optimal conditions for aggressive tumor presentation: tumors appearing after 2 weeks and lesions in multiple organs (4) We also did a comparison of a reduced number of MTT (5) and MPC (6) cells and found tumors developed earlier than when more MPC cells are injected